HighVista Strategies LLC Boosts Stock Position in Enliven Therapeutics, Inc. $ELVN

HighVista Strategies LLC boosted its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 83.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 259,135 shares of the company’s stock after purchasing an additional 117,619 shares during the period. Enliven Therapeutics makes up about 1.3% of HighVista Strategies LLC’s holdings, making the stock its 18th largest holding. HighVista Strategies LLC’s holdings in Enliven Therapeutics were worth $5,304,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ELVN. Affinity Asset Advisors LLC acquired a new position in shares of Enliven Therapeutics in the second quarter valued at approximately $8,024,000. Candriam S.C.A. boosted its position in Enliven Therapeutics by 46.3% during the third quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock worth $12,473,000 after acquiring an additional 192,702 shares during the last quarter. Geode Capital Management LLC grew its stake in Enliven Therapeutics by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after acquiring an additional 63,580 shares during the period. Franklin Resources Inc. grew its stake in Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after acquiring an additional 410,034 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Enliven Therapeutics by 177.4% in the 2nd quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock valued at $730,000 after acquiring an additional 23,261 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the completion of the sale, the insider owned 740,188 shares of the company’s stock, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Anish Patel sold 48,300 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the sale, the chief operating officer owned 215,011 shares of the company’s stock, valued at $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 237,180 shares of company stock worth $6,301,233 in the last three months. 25.90% of the stock is currently owned by insiders.

Enliven Therapeutics Stock Down 3.6%

Shares of ELVN opened at $27.77 on Monday. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.98. The company’s fifty day moving average is $26.70 and its two-hundred day moving average is $22.21. The firm has a market cap of $1.66 billion, a PE ratio of -14.93 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ELVN. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.